Sigyn Therapeutics 

Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and lipoteichoic acid; various viral pathogens; harmful hepatic toxins; CytoVesicles; and significant pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6. The company is headquartered in San Diego, California.